BRAF mutant/MSS cancers of the serrated pathway have been found to have a comparably high rate of p53 mutation as the BRAF wild-type cancers, whereas BRAF mutant/MSI cancers were confirmed to have a low rate of mutation [9]. This evidence concerns the gene BRAF and cancer.